HTG Molecular Diagnostics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 6.5 million compared to USD 4.85 million a year ago. Basic loss per share from continuing operations was USD 9.72 compared to USD 9.6 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | -.--% | -.--% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-51.68% | 2.38B | |
+25.12% | 2.01B | |
-8.77% | 1.55B | |
+22.81% | 1.31B | |
-21.62% | 912M | |
-3.09% | 776M | |
-32.86% | 775M | |
-25.90% | 621M | |
+19.58% | 582M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022